Table 1.
Patient characteristics at baseline
| Usual care (n = 49) | Self-management (n = 64) | Regular monitoring (n = 67) | P-value | |
|---|---|---|---|---|
| Age in years, mean (SD) | 63.5 (± 10.3) | 64.3 (± 11.2) | 65.3 (± 9.3) | 0.65 |
| Male sex, n (%) | 25 (51.0) | 42 (65.6) | 47 (70.1) | 0.10 |
| GOLD stage, n (%) | 0.32 | |||
| GOLD I | 11 (22.4) | 13 (20.3) | 8 (11.9) | |
| GOLD II | 29 (59.2) | 42 (65.6) | 45 (67.2) | |
| GOLD III/IV | 9 (18.4) | 9 (14.1) | 14 (20.9) | |
| Lung function, mean (SD)a | ||||
| FEV1 % predicted | 67.0 (± 18.0) | 65.8 (± 16.3) | 62.6 (± 15.3) | 0.32 |
| FEV1 (L) | 1.96 (± 0.68) | 1.98 (± 0.61) | 1.94 (± 0.62) | 0.94 |
| FEV1/FVC | 0.57 (± 0.12) | 0.58 (± 0.10) | 0.56 (± 0.12) | 0.74 |
| Smoking status, n (%) | 0.47 | |||
| Smoker | 14 (30.4) (n = 46) | 22 (37.3) (n = 59) | 19 (30.6) (n = 62) | |
| Former smoker | 26 (56.5) (n = 46) | 28 (47.5) (n = 59) | 37 (59.7) (n = 62) | |
| GP-diagnosed exacerbations in previous 24 months, mean (SD) | 0.8 (± 1.1) | 1.5 (± 2.0) | 1.0 (± 1.2) | 0.08 |
| Pulmonary medication, n (%) | ||||
| No medication | 19 (38.8) | 12 (18.8) | 18 (26.9) | 0.06 |
| Long-acting bronchodilators | 25 (51.0) | 35 (54.7) | 39 (58.2) | 0.80 |
| Inhaled corticosteroids | 19 (38.8) | 41 (64.1) | 34 (50.7) | 0.04 |
a
Post-bronchodilator measurements. FEV1 = forced expiratory volume in 1 second. FVC = forced vital capacity. GOLD = Global initiative for chronic Obstructive Lung Disease. SD = standard deviation. Denominators vary owing to missing values